Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2015 Publisher: Thornton & Ross Ltd, Linthwaite Laboratories, Huddersfield, HD7 5QH
Ephedrine should not be given to patients who are being treated with monoamine oxidase inhibitors, or within two weeks of stopping such treatment (see section 4.5).
Ephedrine should not be taken with beta-blockers (see section 4.5).
It should be used with caution in patients receiving halogenated anaesthetics.
Ephedrine nasal drops should not be used concomitantly with other sympathomimetic decongestants.
It should also be avoided in patients with cardiovascular disease, cardiac arrhythmias, cardiomyopathy and peripheral vascular disease, hypertension, hyperthyroidism, hyperexcitability, phaeochromocytoma, closed-angle glaucoma and urinary retention.
Ephedrine nasal drops should not be used after nasal or sinus surgery.
Excessive and/or frequent use of a nasal decongestant should be avoided.
Children under 12 years of age.
Hypersensitivity to ephedrine or to any of the excipients.
Store below 25°C. Do not allow to freeze.
Keep all medicines away from children.
Warning: asthmatics should consult their doctor before using this product.
Ephedrine should be used with care in the elderly and in patients with prostatic hypertrophy, diabetes mellitus or renal impairment.
The product should not be used for longer than 7 days. Avoid contamination during use. Keep away from eyes.
10ml pack label states: do not share the drops with anyone.
10ml pack states: discard any unused drops 2 months after opening.
Do not give to children under 12 years.
MAOIs: Risk of hypertensive crisis. Sympathomimetics such as ephedrine should not be given with MAOIs or within 14 days of stopping treatment (see Section 4.3).
Anti-arrhythmics – including beta-blockers and quinidine: ephedrine may increase the risk of arrhythmias, and block the hypotensive effects of beta-blockers (see Section 4.3);
Adrenergic neurone blockers (such as guanethidine): ephedrine may block the hypotensive effects.
Cardiac glycosides (such as digoxin or digitoxin), or tricyclic antidepressants: ephedrine may increase the risk of arrythmias.
Ergotamine and methysergide: ephedrine may increase the risk of ergotism.
Oxytocin: there is increased risk of hypertension when vasoconstrictor sympathomimetics are given with oxytocin.
Doxapram: there is increased risk of hypertension when sympathomimetics are given with doxapram.
Dexamethasone: ephedrine accelerates the metabolism of dexamethasone.
MAO-B inhibitors (such as rasagiline and selegiline): risk of hypertension.
Theophylline: concomitant use with ephedrine may potentiate the adverse effects.
Volatile anaesthetics: ephedrine should be avoided in patients undergoing anaesthesia with volatile anaesthetics – risk of hazardous arrhythmias (see Section 4.3).
Thyroid hormones: Caution is required with sympathomimetics and thyroid hormones.
Appetite suppressants and amphetamine-like psychostimulants: risk of hypertension.
Antihypertensives such as guanethidine, reserpine and probably methyldopa may diminish the effects of ephedrine.
Tricyclic antidepressants may reduce the effect of sympathomimetics.
Caffeine may enhance the side effects of ephedrine.
Antipsychotics may antagonise the hypertensive effects of sympathomimetics.
This product should not be used in pregnancy or whilst breast feeding unless recommended by a doctor. Ephedrine crosses the placenta and has been associated with an increase in foetal heart rate. Ephedrine has been reported to cause irritability and disturbed sleep in infants when used during breast feeding.
None known.
The following undesirable effects have been reported following use of ephedrine and may arise following use of ephedrine nasal drops. The frequency of adverse effects cannot be estimated from available data, but adverse effects may be minimised by avoiding prolonged or excessive use (see section 4.4).
Metabolism and nutrition disorders: Hyperglycaemia, hypokalaemia.
Psychiatric disorders: hallucinations, paranoia.
Nervous system disorders: Anxiety, restlessness, irritability, tremors, headache, tolerance, dependence, insomnia, dizziness and fainting.
Eye disorders: Mydriasis.
Cardiac disorders: Palpitations, arryhythmias.
Vascular disorders: Hypertension (vasoconstriction with hypertension), vasodilation with hypotension, flushing, impaired circulation to the extremities.
Respiratory, thoracic and mediastinal disorders: dyspnoea.
Gastrointestinal disorders: Nausea, thirst, dry mouth, anorexia, vomiting, increased salivation.
Skin & subcutaneous tissue disorders: Sweating, dermatitis, piloerection.
Musculoskeletal and connective tissue disorders: Muscular weakness.
Renal and Urinary disorders: Difficulty in micturition in patients with prostatic enlargement, urinary retention.
General disorders and administration site conditions: Local irritation, dryness, pain, rebound congestion and drug-induced rhinitis.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
None known.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
